Caribou Bioscience, Inc.
Case Overview
35 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 02/24/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Caribou Bioscience, Inc. |
Court: | Court: Northern District of Georgia |
Case Number: | Case Number: 4:24cv09413 |
Class Period: | Class Period: 07/14/2023 - 07/16/2024 |
Ticker: | Ticker: CRBU |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Caribou Bioscience, Inc. (“Caribou” or the “Company”) (NASDAQ:CRBU) securities during the period of July 14, 2023, to July 16, 2024, inclusive (“the Class Period”). Investors have until February 24, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On June 2, 2024, Caribou released updated clinical data from its ANTLER Phase 1 trial, an early-stage study evaluating CB-010, a cancer treatment part of allogeneic CAR-T therapy. The data suggested that CB-010, the company’s lead product candidate, could rival approved autologous CAR-T therapies in terms of safety, efficacy, and durability. However, the next day, analysts from Evercore ISI downgraded the stock and lowered the price target from $13.00 to $3.00, expressing doubts about CB-010’s competitiveness. Specifically, CB-010’s complete response rates (the percentage of patients with no detectable cancer) and progression-free survival times (the length of time a patient lives without the disease worsening) were lower than those of autologous CAR-T therapies. Concerns were also raised about the enhanced lymphodepletion protocol used in the trial, a pre-treatment process that suppresses the patient’s immune system to improve the therapy’s effectiveness but may carry increased risks of side effects. On this news, Caribou's stock price dropped by $0.735 per share, or approximately 25.52%, from $2.88 per share on June 2, 2024, to close at $2.145 on June 3, 2024.
Then, on July 16, 2024, Caribou disclosed in an SEC filing that it had discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions, or approximately 12%, explaining that the company was undertaking this reduction to extend its cash runway. On this news, Caribou's stock price fell $0.09 per share, or approximately 3.3%, from $2.73 per share on July 16, 2024, to close at $2.64 on July 17, 2024.
The lawsuit alleges that the Company and its executives made false and misleading statements about CB-010’s potential, overstated its clinical and commercial prospects, and failed to disclose risks related to the company’s financial and operational position.
On June 2, 2024, Caribou released updated clinical data from its ANTLER Phase 1 trial, an early-stage study evaluating CB-010, a cancer treatment part of allogeneic CAR-T therapy. The data suggested that CB-010, the company’s lead product candidate, could rival approved autologous CAR-T therapies in terms of safety, efficacy, and durability. However, the next day, analysts from Evercore ISI downgraded the stock and lowered the price target from $13.00 to $3.00, expressing doubts about CB-010’s competitiveness. Specifically, CB-010’s complete response rates (the percentage of patients with no detectable cancer) and progression-free survival times (the length of time a patient lives without the disease worsening) were lower than those of autologous CAR-T therapies. Concerns were also raised about the enhanced lymphodepletion protocol used in the trial, a pre-treatment process that suppresses the patient’s immune system to improve the therapy’s effectiveness but may carry increased risks of side effects. On this news, Caribou's stock price dropped by $0.735 per share, or approximately 25.52%, from $2.88 per share on June 2, 2024, to close at $2.145 on June 3, 2024.
Then, on July 16, 2024, Caribou disclosed in an SEC filing that it had discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions, or approximately 12%, explaining that the company was undertaking this reduction to extend its cash runway. On this news, Caribou's stock price fell $0.09 per share, or approximately 3.3%, from $2.73 per share on July 16, 2024, to close at $2.64 on July 17, 2024.
The lawsuit alleges that the Company and its executives made false and misleading statements about CB-010’s potential, overstated its clinical and commercial prospects, and failed to disclose risks related to the company’s financial and operational position.